23,978 Shares in RxSight, Inc. (NASDAQ:RXST) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. purchased a new position in RxSight, Inc. (NASDAQ:RXST - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,978 shares of the company's stock, valued at approximately $824,000. Balyasny Asset Management L.P. owned about 0.06% of RxSight as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Private Trust Co. NA purchased a new position in shares of RxSight in the fourth quarter valued at about $34,000. Coppell Advisory Solutions LLC increased its position in shares of RxSight by 108.9% in the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock valued at $44,000 after acquiring an additional 672 shares during the period. Arcadia Investment Management Corp MI bought a new position in RxSight during the 4th quarter valued at approximately $46,000. Harbor Investment Advisory LLC purchased a new stake in RxSight in the 4th quarter worth approximately $52,000. Finally, Global Retirement Partners LLC purchased a new stake in RxSight in the 4th quarter worth approximately $69,000. 78.78% of the stock is owned by institutional investors.

RxSight Price Performance

Shares of RXST stock traded down $0.06 on Tuesday, hitting $16.27. 139,492 shares of the stock traded hands, compared to its average volume of 676,516. The firm has a market cap of $660.96 million, a price-to-earnings ratio of -19.64 and a beta of 1.32. RxSight, Inc. has a 52 week low of $12.53 and a 52 week high of $64.50. The firm has a 50 day simple moving average of $17.89 and a two-hundred day simple moving average of $29.71.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company's revenue was up 28.5% on a year-over-year basis. During the same period last year, the firm earned ($0.25) EPS. Sell-side analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on RXST shares. Wells Fargo & Company upgraded shares of RxSight from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $17.00 to $25.00 in a report on Monday. Bank of America reiterated an "underperform" rating and set a $22.00 price target (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. UBS Group cut shares of RxSight from a "buy" rating to a "neutral" rating and reduced their price target for the company from $45.00 to $16.00 in a research report on Wednesday, April 9th. Stifel Nicolaus reduced their price target on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $43.00 price target on shares of RxSight in a research report on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $37.90.

Insider Buying and Selling at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. The trade was a 22.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 9.36% of the stock is currently owned by insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.